2 Information about sebelipase alfa

Marketing authorisation indication

2.1

Sebelipase alfa (Kanuma, Alexion) is indicated for 'long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency'.

Dosage in the marketing authorisation

2.2

The dosage schedule is available in the summary of product characteristics for sebelipase alfa.

Price

2.3

The list price of sebelipase alfa is £6,286 for a 20 mg vial (excluding VAT; company submission).

2.4

The company has a commercial arrangement. This makes sebelipase alfa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.